Acompanhe as Notícias da Recifes

A nationwide Veterans Affairs (VA) study comparing two leading treatments for metastatic prostate cancer may help doctors choose the right drug for each patient, said a Rutgers Cancer Institute physician-scientist whose invited editorial accompanies the research.

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that treatment is working. A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is an indicator of improved patient survival. The

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and inves

A protein secreted by common cancer types makes blood vessels leakier to allow metastatic tumors to form in the lungs, according to a study led by investigators at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. The discovery could lead to new ways of monitorin

Most cancer deaths are caused not by the initial tumor but by the spread of cancer cells to distant organs in the process called metastasis. Since it occurs at the cellular level, the earliest stages of metastasis are difficult to observe in patients. A new study, published in Sc